Interleukin 28B Genetic Polymorphisms and Viral Factors Help Identify HCV Genotype-1 Patients who Benefit from 24-Week Pegylated Interferon plus Ribavirin Therapy | Zendy

ChenHua Liu | Zendy; ChengChao Liang | Zendy; ChunJen Liu | Zendy; TaiChung Tseng | Zendy; ChihLin Lin | Zendy; ShengShun Yang | Zendy; TungHung Su | Zendy; ShihJer Hsu | Zendy; JouWei Lin | Zendy; Jun-Herng Chen | Zendy; PeiJer Chen | Zendy; DingShinn Chen | Zendy; JiaHorng Kao | Zendy

Open Access

Interleukin 28B Genetic Polymorphisms and Viral Factors Help Identify HCV Genotype-1 Patients who Benefit from 24-Week Pegylated Interferon plus Ribavirin Therapy

Author(s) -

ChenHua Liu,

ChengChao Liang,

ChunJen Liu,

TaiChung Tseng,

ChihLin Lin,

ShengShun Yang,

TungHung Su,

ShihJer Hsu,

JouWei Lin,

Jun-Herng Chen,

PeiJer Chen,

DingShinn Chen,

JiaHorng Kao

Publication year - 2011

Publication title -

antiviral therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.747

H-Index - 87

eISSN - 2040-2058

pISSN - 1359-6535

DOI - 10.3851/imp2026

Subject(s) - ribavirin , viral load , pegylated interferon , medicine , interleukin 28b , genotype , gastroenterology , combination therapy , immunology , hepatitis c virus , biology , virus , genetics , gene

Interleukin 28B (IL28B) single nucleotide polymorphism (SNP) genotypes and viral factors can predict sustained virological response (SVR) in HCV genotype-1 (HCV-1) patients receiving 48 weeks of pegylated interferon and ribavirin. Whether these factors would identify those patients who can benefit from a shorter duration of therapy remains unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research